glp-1 xlr8 Generic Liraglutide Approved, Marking First Generic RA Indicated Specifically for Weight Management in the US GLP-1 Natural Booster

CrossRef Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice Martin Ho Yin Yeung, Ka Long Leung, Lai Yuen Choi, Jung Sun Yoo, Susan Yung, Pui-Kin So, Chi-Ming Wong Frontiers in Pharmacology.2022;[Epub] CrossRef GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo Kidney Research and Clinical Practice.2022

Trophic Effects of Glicentin on Rat Small-Intestinal Mucosa

Patients on GLP-1 medications often have compromised healing for multiple reasons: nutritional deficiency, dry mouth affecting tissue health, possible acid damage to surrounding areas, and in some cases the metabolic issues that led them to need these medications in the first place

Obesity and response to anti-tumor necrosis factor- agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

With Catalent sale concerns, Lilly allegedly adds GLP-1 CDMOs Eli Lilly has inked deals with CDMOs National Resilience and BSP Pharmaceuticals for the fill/finish of GLP-1 Zepbound and Mounjaro (both tirzepatide), according to media reports